These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 34268872)

  • 1. Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC).
    Xu Z; Li T; Hu X; Hao X; Xing P; Li J
    Thorac Cancer; 2021 Sep; 12(17):2360-2368. PubMed ID: 34268872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness and safety of recombinant human endostatin plus PD-1 inhibitors and chemotherapy as first-line treatment for EGFR/ALK-negative, advanced or metastatic non-small cell lung cancer.
    Zhang J; Lv PY; Zhao X; Liu ML; Qiu LP; Yang ZZ; Sun SJ; Zhang GQ
    BMC Cancer; 2024 Aug; 24(1):967. PubMed ID: 39112947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: A two-center retrospective study.
    Yao J; Wang Z; Sheng J; Wang H; You L; Zhu X; Pan H; Han W
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107033. PubMed ID: 33039958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
    Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
    Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
    Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
    Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter, real-world study on effectiveness and safety of first-line modified PD-1 inhibitors with chemotherapy in advanced non-small cell lung cancer (aNSCLC) with drive gene-negative.
    Li T; Chen C; Liu L; Qin J; Qiu L; Wang A; Dong W; Zhang G; Li Y; Zhao L; Zhang F; Hu Y
    Cancer Med; 2024 Feb; 13(3):e7024. PubMed ID: 38400661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study.
    Lin CC; Curigliano G; Santoro A; Kim DW; Tai D; Hodi FS; Wilgenhof S; Doi T; Sabatos-Peyton C; Szpakowski S; Chitnis S; Xyrafas A; Gutzwiller S; Pastore A; Mach N
    BMJ Open; 2024 Aug; 14(8):e079132. PubMed ID: 39209782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy or antiangiogenic therapy plus chemotherapy as first-line treatment of patients with PD-L1(-) advanced non-squamous non-small cell lung cancer in a Chinese cohort.
    Xia R; Li Y; Yang L; Huang M
    Cancer Med; 2023 Jul; 12(13):14282-14292. PubMed ID: 37212483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Yang Y; Luo H; Zheng XL; Ge H
    Clin Transl Oncol; 2021 Jun; 23(6):1117-1127. PubMed ID: 33211281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC.
    Takeyasu Y; Yoshida T; Shibaki R; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Yamamoto N; Motoi N; Ohe Y
    Clin Lung Cancer; 2021 Mar; 22(2):127-133.e3. PubMed ID: 33183972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
    Ferrara R; Mezquita L; Texier M; Lahmar J; Audigier-Valette C; Tessonnier L; Mazieres J; Zalcman G; Brosseau S; Le Moulec S; Leroy L; Duchemann B; Lefebvre C; Veillon R; Westeel V; Koscielny S; Champiat S; Ferté C; Planchard D; Remon J; Boucher ME; Gazzah A; Adam J; Bria E; Tortora G; Soria JC; Besse B; Caramella C
    JAMA Oncol; 2018 Nov; 4(11):1543-1552. PubMed ID: 30193240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer.
    Miyawaki T; Kenmotsu H; Mori K; Miyawaki E; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Harada H; Endo M; Ohde Y; Takahashi K; Takahashi T
    Clin Lung Cancer; 2020 Sep; 21(5):e405-e414. PubMed ID: 32205040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
    Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
    Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.
    Shi Y; Duan J; Guan Q; Xue P; Zheng Y
    Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
    Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
    JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.